Lexicon Pharmaceuticals, Inc.
LXRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $236,343 | $338,329 | $316,550 | $573,869 |
| - Cash | $66,656 | $22,465 | $46,345 | $64,065 |
| + Debt | $108,397 | $106,064 | $55,294 | $2,279 |
| Enterprise Value | $278,084 | $421,928 | $325,499 | $512,083 |
| Revenue | $31,081 | $1,204 | $139 | $298 |
| % Growth | 2,481.5% | 766.2% | -53.4% | – |
| Gross Profit | $30,465 | -$57,768 | -$52,377 | -$54,748 |
| % Margin | 98% | -4,798% | -37,681.3% | -18,371.8% |
| EBITDA | -$184,290 | -$169,756 | -$100,033 | -$86,798 |
| % Margin | -592.9% | -14,099.3% | -71,966.2% | -29,126.8% |
| Net Income | -$200,403 | -$177,119 | -$101,944 | -$87,758 |
| % Margin | -644.8% | -14,710.9% | -73,341% | -29,449% |
| EPS Diluted | -0.63 | -0.8 | -0.62 | -0.61 |
| % Growth | 21.3% | -29% | -1.6% | – |
| Operating Cash Flow | -$178,780 | -$161,897 | -$88,851 | -$87,017 |
| Capital Expenditures | -$1,031 | -$470 | -$1,326 | -$1,221 |
| Free Cash Flow | -$179,811 | -$162,367 | -$90,177 | -$88,238 |